<DOC>
	<DOCNO>NCT02382939</DOCNO>
	<brief_summary>This trial conduct Europe Asia . The aim trial compare safety weekly dosing somapacitan ( administer investigational pen ) daily Norditropin速 FlexPro速 ( somatropin deliver within prefilled pen ) 26 week previously human growth hormone ( hGH ) treat adult growth hormone deficiency .</brief_summary>
	<brief_title>A Trial Compare Safety Once Weekly Dosing Somapacitan With Daily Norditropin速 FlexPro速 26 Weeks Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Male female least 18 year age 79 year age time sign informed consent Adult growth hormone deficiency diagnose 6 month longer ( defined 180 day ) prior screen Treatment hGH ( human growth hormone ) least 6 month screen If applicable , hormone replacement therapy hormone deficiency , adequate stable least 90 day prior randomisation judge investigator Active malignant disease history malignancy . Exceptions exclusion criterion : Resected situ carcinoma cervix squamous cell basal cell carcinoma skin complete local excision . / Subjects GHD ( growth hormone deficiency ) attribute treatment intracranial malignant tumour leukaemia , provide recurrencefree survival period least 5 year document subject 's file For patient surgical removal debulking pituitary adenoma benign intracranial tumour within last 5 year : Evidence growth pituitary adenoma benign intracranial tumour within last 12 month ( define equal 365 day ) randomisation . Absence growth must document two postsurgery MRI CT scan . The recent MRI CT scan must perform equal 9 month ( define equal 270 day ) prior randomisation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>